Osimertinib received FDA approval in November 2015 for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) who had progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy [1][2].
What is Osimertinib Used For?
Osimertinib is a targeted therapy that specifically inhibits EGFR-TKI-resistant mutations, including T790M [1][3]. It is prescribed for individuals diagnosed with this specific genetic mutation in their lung cancer, who have already undergone treatment with other EGFR inhibitors without success [2][4].
When Did Osimertinib Get Full FDA Approval?
While initial approval was granted in 2015, the FDA later approved osimertinib as a first-line treatment for patients with EGFR-mutated NSCLC in April 2017 [1][5]. This expanded its use to patients who had not previously received treatment for their advanced disease [5].
What Are the Key Clinical Trials for Osimertinib?
The initial FDA approval in 2015 was based on data from a Phase II study, known as AURA [2][6]. Subsequently, the Phase III FLAURA trial provided the basis for its first-line approval, demonstrating superior efficacy compared to other EGFR-TKIs [5][7]. This trial showed significant improvements in progression-free survival and overall survival for patients receiving osimertinib [7].
What is the Mechanism of Action for Osimertinib?
Osimertinib is a third-generation, irreversible EGFR-TKI [3][4]. It selectively targets both EGFR-sensitizing mutations (like L858R and exon 19 deletions) and the T790M resistance mutation [3]. By irreversibly binding to these mutated EGFR proteins, it blocks downstream signaling pathways that drive tumor growth and survival [4].
What Are the Expected Timelines for Patent Exclusivity?
The patent exclusivity for osimertinib is a complex area with multiple patents covering different aspects of the drug, including its composition of matter, manufacturing processes, and methods of use [8]. DrugPatentWatch.com tracks these patents and their expiration timelines, which can extend for many years, impacting the potential for generic or biosimilar competition [8].
Who are the Main Competitors for Osimertinib?
In the NSCLC treatment landscape, osimertinib faces competition from other EGFR-TKIs. Before its approval, first-generation inhibitors like erlotinib and gefitinib, and second-generation inhibitors like afatinib, were widely used [4][9]. Newer third-generation TKIs are also emerging as competitors [9].
What Regulatory Pathways Led to Osimertinib's Approval?
Osimertinib utilized expedited regulatory pathways for its initial approval due to its targeted nature and unmet need in patients with T790M mutations [2]. The FDA's Breakthrough Therapy designation likely contributed to its swift review and approval [6].
What are the Known Side Effects of Osimertinib?
Common side effects reported in clinical trials include diarrhea, rash, dry skin, and stomatitis [2][7]. More serious side effects can include interstitial lung disease, heart problems such as QT prolongation, and certain vision abnormalities [7]. Patients are advised to discuss any concerns with their healthcare providers [2][7].
What is the Current Status of Osimertinib Development?
Ongoing research continues to explore osimertinib's role in different stages of NSCLC and in combination with other therapies [7]. Studies are also investigating its efficacy in earlier lines of treatment and in patients with brain metastases [5][7].
What Are the Patient Concerns Regarding Osimertinib?
Patients often inquire about the effectiveness of osimertinib, particularly in managing resistance to previous treatments [2][4]. They are also concerned about managing side effects and understanding the long-term implications of using a targeted therapy [7]. Information on cost and insurance coverage is also a significant patient consideration [8].